PDS Biotechnology Corp (PDSB)

[rolvram]

PDS Biotech to Host Key Opinion Leader Event on December 17 at 12 p.m. ET
PDS Biotechnology Corporation
Tue, December 3, 2024 at 8:00 AM EST 7 min read


In This Article:
PDSB
+0.92%
PDS Biotechnology Corporation
PDS Biotechnology Corporation
Discussion topics to include pathology and prevalence of HPV16-positive head and neck cancer, VERSATILE-003 Phase 3 clinical trial design and initiation

PRINCETON, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced a Key Opinion Leader (“KOL”) event to discuss the pathology and growing prevalence of HPV16-positive head and neck squamous cell carcinoma (“HNSCC") as well as the Company’s upcoming VERSATILE-003 Phase 3 clinical trial of Versamune® HPV + pembrolizumab for first-line treatment of recurrent and/or metastatic HPV16-positive HNSCC.


The KOL event will take place on Tuesday, December 17, 2024, at 12 p.m. ET and panel participants include:

Francis “Frank” Worden, M.D., Rogel Cancer Center, University of Michigan

Kevin Harrington, MBBS, Ph.D., The Institute of Cancer Research, United Kingdom

The event will be moderated by Kirk Shepard, M.D., PDS Biotech’s Chief Medical Officer.

Webcast and Registration Details

Date: Tuesday, December 17, 2024
Time: 12 p.m. - 1:30 p.m. ET